MicroPort CardioFlow Medtech Corporation

2023 Interim Results Presentation



August 2023

Disclaimer

This presentation was prepared by MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司) (the "Company") solely for use at the presentation held in August 2023.

The information contained in this presentation has not been reviewed by any regulatory authority in any jurisdiction nor independently verified. No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information contained herein. The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. Neither the Company nor any of its affiliates, advisers or representatives accepts any liability whatsoever for any actual or consequential loss or damages howsoever arising from the provision or use of any information contained in this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such alternations, modifications or changes.

This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as "expects", "plan", "will", "estimates", "projects", "intends", or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward- looking statements contained in this presentation to reflect future events or circumstances. Accordingly, you should not place undue reliance on any forward-looking information.

This presentation is for information purposes only and does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, any of its holding companies, or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the business, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document does not constitute a prospectus or an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance of Hong Kong and may only be made available to professional investors within the meaning of the Securities and Futures Ordinance of Hong Kong. The receipt of this document by any recipient is not to be taken as constituting the receipt of investment advice or an establishment of customer or client relationship.

Agenda

Business Highlights 04

Product Pipeline Update 09-15

Appendices 20-28

Sales & Marketing Review 05-08

Financial Review 16-19

Business Review

MicroPort™ 心通医疗

1H23 Highlights: Exceptional Commercialization and Sharpened Pipeline

Key Indicators

Revenue	RMB 176mn	+ 41.4%YOY
GPM	66.1%	+ 2.4 pptsYOY
Operating Expenses%[1]	127.5%	- 12.4 pptsYOY
Implantation Volume[2]	1,999	49.7%YOY
Covered Hospital	505 centers	35.8%YOY
Sales Team	~200 staff	17.2%YOY

Robust Financials

- **Revenue +41.4%** YOY with **overseas revenue growth** at **243.1%** YOY thanks to the accelerated commercialization progress of our TAVI products
- **GPM** increased by **2.4 ppts** YOY while **operating expenses ratio[1]** narrowed down by **12.4 ppt** YOY
- **Cash balance[3]** at **RMB2.0 billion** as of June 30, 2023

Operational Highlights

- **Average domestic monthly implantation volume** > **320** in 1H23, **+46.5%** YOY and **+55.5%** compared to 2H22
- **Hospital coverage +35.8%** YOY to **505**, gaining share in top hospitals and expanding reach in lower-tier cities
- **VitaFlow Liberty®** and **Alwide® Plus** registered in **3** overseas countries, completed commercial implantation in **60+** hospitals, with **implantation volume growth** of **+245.5%** YOY
- **VitaFlow Liberty®** received registration approval in **Thailand** and made progress in **CE registration**
- **AccuSniper™ Double-Layer Balloon Catheter** received NMPA approval in August
- **VitaFlow®III** completed design freeze, expected to submit for NMPA approval in Q4
- **Self-developed TMVR** completed more FIM cases with good MR reduction and QoL improvement at follow-up periods up to a year
- **AltaValve™** pre-submitted IDE application to FDA, expected to be the world's first TMVR therapy with atrium-only fixation

1. *Refers to the total amount of research and development, distribution and administrative expenses as percentage of revenue;*
2. *Refers to number of procedures performed using VitaFlow® or VitaFlow Liberty ® rather than the number of products implanted;*
3. *Including cash, cash equivalents and time deposits.*

Total Solutions Promotion

MicroPort™
心通医疗

Increasing TAVI Accessibility and Affordability Supporting Sustained Growth

Increasing Health Awareness

Significantly Underpenetrated Therapy

Patient Discovery and Referral

Deepened Hospital Coverage

Enhanced Medical Insurance Reimbursement

More Independent Physicians[1]

Rapid Industry Growth[2] with Fast Share-Gaining

CAGR (2019-2022): whole Industry – 50.7%; CardioFlow – 182.2%



1. *Physicians who can perform TAVI with our products independently ;*
2. *Source: "Structural Heart Diseases Annual Report 2022" and data collected by our our sales & marketing team.*

Highly-efficient Total Solutions Promotion Team with Strong Value Propositions

Hospitals

- Covered hospitals **+35.8%** to **505**, with **per hospital implantation** increased by about **8%**
- Strong implantation growth in top 20 centers (**+56.0%**) and non-top-100 centers (**+55.2%**) [1]
- **Multi-pronged marketing strategy** targeting different tiers of hospitals suited for their varied needs

Patients

- **Effective patient discovery and referral schemes** with strong support by MicroPort® Group and enhanced awareness of hospitals
- Leveraging **digital tools** for **full-process health management** that optimizes health outcomes and reducing patient anxiety
- Comprehensive **affordability solutions** for easing financial burden of patients

Physicians

- Conference & trainings to introduce **latest medical device innovation** and incubate more independent physicians[2] (**+59** to **261**)
- **Peri-operative support** to help choose the best-fit size, make treatment plan and optimize procedure results

1. *Our sales & marketing team divide covered hospitals into 3 tiers based on their estimated total TAVI implantation volume in 2022 : 1) top 20 centers; 2) top 21-100 centers; 3) centers that fall below top 100;*
2. *Physicians who can perform TAVI with our products independently.*

Overseas Expansion Leveraging MicroPort® Channels and Brand Influence

Overseas expansion led by core TAVI products

- ***Revenue of 6.29mn RMB***
- ***VitaFlow Liberty®, Alwide® Plus and Angelguide®*** *entered* ***5*** *overseas countries and multiple registrations ongoing (including CE)*
- *Used in* ***63*** *hospitals with* ***11*** *proctors,* ***with 76 implantations in 1H23***
- *Visited* ***core EU target countries*** *to understand competitive landscapes and prepare for the upcoming product launch*

Enhanced recognition for TAVI treatment

- *Attended* ***world-renowned conferences*** *highlighting product differentiation including anti-PVL design, high calcium case treatment, AR patient treatment, etc.*
- *Accumulating real-world case experience and database to strengthen brand recognition*
- *Leveraging mature MicroPort® channel network to quickly penetrate overseas market*



16 Mar, CSC, Spain

24 Mar, VALVE in Rio, Brazil

21 Apr, Structural Summit SBHCI, Brazil

16 May, EuroPCR, France

1 Jun, Police General Hospital Workshop, Thailand

2-4 August, SOLACI, Brazil

Product Pipeline Update

MicroPort™ 心通医疗

Innovative and High-quality Total Solutions for Structural Heart Diseases



TAVI

- **2** launched, **3** under R&D
- VitaFlow Liberty® significantly reduced VIV incidence
- VitaFlow®III embedded with an innovative steerable retrievable delivery system for optimal TAVI outcomes
- Innovative TAVI product developed for AR indication



Procedural Accessories

- **4** launched, **1** pending approval and **1** under R&D
- Alwide® Plus balloon catheter CE registration in progress and newly received registration approval in Russia
- AccuSniper™ Double-Layer Balloon Catheter received NMPA approval



TMV

- **4** pipeline products: **2** TMVR and **2** TMVr
- Inhouse R&D + Collaboration with global partners 4C Medical and Valcare
- Self-developed TMVR product 1-year follow-up shows good safety and efficacy, marking the world' s first dry-tissue TMVR system with clinical application

TTV

- **3** pipeline products: **1** repair and **2** replacement
- In-house R&D + Collaboration with global partner 4C
- Self-developed TTVR product overcame technical difficulties and iterated designs

VitaFlow® Family Products: Positive Clinical Trial Results and KOL Endorsements

VitaFlow®

Transcatheter Aortic Valve Implantation System



Relatively lower all-cause mortality rate

1-year follow-up period

0 moderate or severe PVL

2-year follow-up period

0 major (disabling) stroke

5-year follow-up period

81.8% patient survival rate

Longer follow-up ongoing…

VitaFlow Liberty®

Transcatheter Aortic Valve Implantation System



Significantly reduced intraoperative valve-in-valve incidence

Product	VIV Incidence
VitaFlow Liberty®	**4.3%** (7/163)
VitaFlow®	8.2% (9/110)

During the procedure

100% retrieval success

30-day follow-up period

0 major (disabling) stroke

VitaFlow ®III Self-Expanding

Transcatheter Aortic Valve Implantation System



Steerable catheter expected to significantly improve patient outcomes won strong KOL endorsements

> The unique bending control of VitaFlow® III is highly innovative. It can adapt well to a wide range of patient anatomies and respond well to unmet clinical needs.

> VitaFlow® III embodies a global leading system that represents the next generation of self-expanding TAVI products. We look forward to the product launch.

All-Cause Mortality Comparison with Peers[1]

Follow-up Time	VitaFlow®	Peer I	Peer II
30-day	**0.9%**	5%	3.3%
1-year	**2.7%**	5.9%	14.2%
2-year	**4.5%**	8.9%	22.2%
3-year	**10.9%**	12.9%	32.9%
4-year	**12.7%**	14.9%	N/A
5-year	**18.2%**	34.1%	55.3%

1. Please refer to Appendix 2 for full clinical data comparison.

MicroPort 心通医疗

VitaFlow®III Self-Expanding: Steerable Catheter to Address Clinical Painpoints

TAVI painpoints: release stability, coaxiality, PVL …

Carryover THV Design

Signature VitaFlow® family valve & stent design

Valve tissue

- Bovine pericardium to ensure better durability
- VITAL-X™ anti-calcification treatment

Stent

- Mixed-density mesh design, making it flexible enough to pass the aortic valve and strong enough to suit high-calcification patients and keep in place
- Balanced waist design that provides large EOA and release stability
- First double-layer PET skirt to reduce PVL





Feature Improvement (Delivery System)

- **Bending control:** catheter articulation for improved delivery and valve positioning that suits challenging anatomy and underpins improved patient outcomes
- **Release limit:** higher release safety and easier control
- **Low Profile:** Reduced profile for improved vascular complications

Progress and Upcoming Milestones

- Design freeze
- FIH scheduled in Q4
- NMPA submission expected in Q4

Self-developed TMVR Product: FIM Study Confirming Safety and Efficacy

TMVR painpoints: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve…

Product Features

- Good anchoring performance
- **Low profile of stent design reducing LVOTO risks**
- **Effective mitral valve orifice area**
- **Self-developed anti-calcification treatment**, including dry tissue platform technology to improve durability
- Low damage to the apical tissue
- Ease-of-use and accurate positioning, device time is only 15-25 mins

Progress and Upcoming Milestones

- **Completed several CU cases with follow-up periods up to a year**
- Ongoing multi-center patient screening
- Good MR reduction, no PVL and no LVOTO with improved cardiac function and quality of life
- Expected to start type test and provide more size selection by year end

World's first dry-tissue TMVR system with clinical application
No calcification in 90-day and 180-day long term animal study (sheep model)



AccuSniper™: The World's Only Double-Layer Balloon Catheter Designed for TAVI with Excellent Release Stability and Puncture Resistance

Dilation balloon painpoints: release instability, severe calcification/sharp object puncturing the balloon, over-expansion damaging the anatomical structure, long-term bloodflow occlusion affecting cardiac function, intima injury…

Product Features

- The world's only double-Layer dilation balloon designed for TAVI with **excellent release stability**
- Hybrid polymer materials significantly **improve puncture resistance and ensure surgical safety**
- **Ultra-low compliance** that improves dilation accuracy, avoids annulus tear or other structural damage
- High burst pressure helps **effective expansion in severe stenosis and bicuspid aortic valve cases**
- Rapid filling/retraction, quicker work response, **avoiding myocardial ischemia**
- Ability to return to the original shape, **reducing intima damage during withdrawl**

Progress and Outlook

- Recently approved by NMPA for marketing
- Product innovation based clinical painpoints to strengthen our total solution for TAVI
- Helps TAVI physicians deal with challenging cases
- Provides economic treatment option for patients



Pipeline Overview with 2023 Milestones

Inhouse Development

TAVI

AS

VitaFlow Liberty® CE
CE mark approval expected in Q4

VitaFlow ® III Self-Expanding
NMPA submission in Q4

Balloon Expandable
Animal studies
FTO Analysis

AR

TAVI AR
Animal studies

TMV

TMVR

TMVR
Type test kickoff expected in Q4

TMVr

Edge to Edge
Animal studies

TTV

TTVR

TTVR product
Design stage

TTVr

Edge to Edge
Design Stage

Procedural Accessories

Alwide® Plus Balloon Catheter
CE mark approval expected in Q4

AccuSniper™ Double-Layer Balloon Catheter
Received NMPA Approval

Expandable Sheath
Design Stage

BD Projects

TMVR

AltaValve (4C)
Global EFS completion expected in Q4

TMVr

AMEND (Valcare)
Ongoing global EFS

TTVR

TTVR product (4C)
Design Stage

Financial Review

MicroPort™ 心通医疗

Rapid Revenue Growth Coupled by Increase in Gross Profit

Revenue (RMB'000)



Gross Profit (RMB'000)



Gross Profit Margin (%)



- **Overall revenue** increased by 41% in 1H23, driven by continued hospital penetration of our TAVI products and strong sales volume growth
- **Overseas revenue contribution** reached RMB6.29 mn in 1H23
- **GPM** further improved by 2.4 ppts in 1H23 thanks to our strengthened bargaining power, domestic sourcing, improved production yield rate and manufacturing efficiency

Investment in R&D and Commercialization with Effective Cost Control

We focused on strengthening our R&D pipelines, keeping our commercialization competitiveness and saving on administrative expenses.
Our operational expenses[1] vs revenue ratio decreased by 12.4 percent points from 139.9% in 1H 2022 to 127.5% in 1H 2023.

R&D Expenses (RMB'000)

% of revenue

63.8% 62.1%

- Increased R&D expenses due to our continuous investments on the new and on-going R&D projects



Distribution Expenses (RMB'000)

% of revenue

48.9% 49.2%

- Increased staff cost and marketing activities along with the market penetration of our products



Administrative Expenses (RMB'000)

% of revenue

27.2% 16.2%

- Decreased Administrative expense mainly due to effective cost control measures



1. *Refers to the total amount of research and development, distribution and administrative expenses as percentage of revenue.*

Sufficient Cash Reserve for Future Development and Global Expansion

Cash Outflow from Operating Activities

(RMB'000)



Cash and Cash Equivalents*

(RMB'000)



We maintained sufficient cash balance as of 30, Jun 2023 of RMB2.0 billion*, which can support us to strengthen our pipelines on R&D investment, expand our production capacity and further commercial penetration.

*Including pledged and time deposits

Appendices

Appendix 1: Overview of Product Pipeline

Products				Pre-clinical	Clinical trial	Registration
Aortic valve products	VitaFlow® System	VitaFlow®		Launched; Successfully registered in Argentina and Thailand		
		Alwide® balloon catheter*		Launched; Successfully registered in Argentina and Thailand		
	VitaFlow Liberty® System	VitaFlow Liberty® *(Retrievable)*	★	Launched; Successfully registered in Argentina , Colombia and Thailand; CE Marking registration and registration in emerging markets in progress		
		Angelguide® tip-preshaped super stiff guidewire*		Launched; Successfully registered in Argentina and Colombia		
	VitaFlow® III *(Steerable delivery system)*		★	Design freeze		
	VitaFlow® Novo Generation *(Brand new PAV design and new anti-calcification technology)*		★	Design stage		
	VitaFlow® Balloon Expandable *(New anti-calcification technology)*			Animal studies		
Mitral valve products	**Replacement product** *(self-development)*		★	FIM Study		
	AltaValve – Replacement product *(Partnership with 4C Medical – commercialization rights in China)*		★	Preparing for FIM; Pre-submitted IDE application to FDA		
	Edge to edge repair product *(self-development)*		★	Preparing for FIM		
	Amend – Repair product *(Partnership with Valcare – commercialization rights in China)*			Preparing for FIM; Early feasibility studies		
Tricuspid valve products	**Self-developed replacement product**		★	Design stage		
	Edge to edge repair product *(self-development)*			Design stage		
	Replacement product *(Partnership with 4C)*			Design stage		
Procedural accessories	**Alwide® Plus balloon catheter**		★ ★	Launched; Successfully registered in Argentina, Colombia, Brazil,Thailand and Russia, CE Marking registration in progress		
	AccuSniper™ double-layer balloon catheter			Received NMPA Approval		
	Alpass® catheter sheath II		▲	NMPA Registration in progress		
	Expandable sheath		▲	Design stage		

China status

Global status

★ Major Progress during the Reporting Period

▲ Among our product candidates, these devices are exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials promulgated by the NMPA, as amended

* These procedural accessories are registered and commercialized offered as part of VitaFlow® or VitaFlow Liberty™ system and are not registered as standalone product in China

Appendix 2: TAVI Products - Clinical Data Comparison

Company	Product	30-days mortality rate[1]	30-days major (disabling) stroke[1]	1-year mortality rate[1]	1-year major (disabling) stroke[1]	1-year moderate to severe PVL rate	1-year major vascular complications	2-year mortality rate[1]	2-year major (disabling) stroke[1]	3-year mortality rate[1]	3-year major (disabling) stroke[1]	4-year mortality rate	4-year major (disabling) stroke	5-year mortality rate	5-year major (disabling) stroke
MicroPort 心通医疗	VitaFlow®	0.9%	0.0%	2.7%	0.0%	0.0%	2.7%	4.5%	0.0%	10.9%	1.8%	12.7%	2.0%	18.2%	2.1%
	VitaFlow Liberty®	5.0%	0.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
启明医疗 VENUSMEDTECH	VenusA-Valve	5.0%	1.0%	6.0%	1.0%	4.2%	6.1%	11.6%	N/A	17.4%	N/A	26.7%	N/A	34.1%	N/A
	VenusA-Plus	4.8%	1.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JC Medical	J-Valve	4.7%	0.0%	5.6%	2.0%	1.1%	N/A	9.1%	2.0%	10.8%	N/A	N/A	N/A	N/A	N/A
Medtronic	CoreValve (U.S Pivotal)	3.3%	3.9%	14.2%	5.8%	6.1%	6.2%	22.2%	6.8%	32.9%	8.1%	N/A	N/A	55.3%	12.3%
Edwards	SAPIEN 3 (U.S. Trial)	2.2%	0.9%*	14.4%	2.4%*	2.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	SAPIEN 3 (China Trial)	0.0%	2.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PEIJIA 沛嘉医疗	TaurusOne	1.7%	N/A	6.7%	N/A	1.0%	4.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	TaurusElite	2.5%	0.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: [1] The data is from pivotal clinical trial of corresponding products and not head-to-head clinical results. VitaFlow® (N=110), VitaFlow Liberty™ (N=60), VenusA-Valve (N=101), VenusA-Plus (N=62), J-Valve (N=107), TaurusOne (N=120), TaurusElite (N=81), CoreValve (N, TAVI =391), SAPIEN 3 China trial (N=50), U.S. trial (N=583)

*: The data marked with * represent the incidences of disabling stroke

Appendix 3: Product Features – TAVI

Category	Product	Features	Progress
TAVI *5 products* *2 launched*	**VitaFlow®III** **Self-Expanding** 	✦ Catheter articulation for improved delivery and valve positioning that suits challenging anatomy and underpins improved patient outcomes ✦ Ease-of-use significantly shortens learning curve ✦ Reduced profile for improved vascular complication outcome	✦ **Design freeze** ✦ **Approval expected in 2024** ✦ Design spoken highly of by KOLs
	VitaFlow® **Novo Generation**	✦ Innovative deployment mechanism for accurate positioning ✦ Fully retrievable with steerable catheter enabling better coaxial property ✦ Dry tissue	✦ **Design stage** ✦ Redesigned for **AR indication**
	VitaFlow® **Balloon Expandable** 	✦ Large cells consistent with VitaFlow® family reducing coronary occlusion risk ✦ Dry tissue	✦ **Completed animal studies** ✦ Positive long-term survival outcomes in chronic animal study
Procedural Accessories *8 products* *4 launched*	**AccuSniper™** **Double-Layer** **Balloon Catheter**	✦ More stable position during inflation ✦ High burst pressure suits for severe calcification conditions	✦ **NMPA Approval received in 2023**
	Expandable sheath	✦ Reducing access complications ✦ Low profile	✦ **Design stage**

Note: The above chart is not exhaustive of all our TAVI and procedural accessory products.

Appendix 3: Product Features – TMV

Category	Product	Features	Progress
TMVr*	**TMVr product** (In-house development)	✦ Differentiated deployment for ease of use ✦ Unique lock mechanism for stable leaflet capture ✦ Low profile	✦ **Animal Studies**
	AMEND (Partnership with Valcare)  AMEND™	✦ Innovative ring design with unique anchoring capabilities ✦ Maintain original mitral valve's structural integrity for long-term performance improvement ✦ Compatible with both transeptal or transapical approaches	✦ **Pre-submitted IDE application to FDA** ✦ Surgical-like results: MR reduction to <2+ ✦ Ongoing patient screening for China case
TMVR**	**TMVR product** (In-house development)	✦ Good Anchoring Performance ✦ Effective Mitral Valve Orifice Area ✦ Low profile of stent design reducing LVOTO risks ✦ Dry tissue	✦ **FIM recruitment** with immediate MR relief and no PVL or LVOTO and positive 1-year follow-up result ✦ Developing new sizes to expand patient cohort coverage
	AltaValve (Partnership with 4C) ALTAVALVE 	✦ Supra-annular fit and atrial-only fixation design overcoming anchoring and fixation difficulties ✦ The only known TMVR device with full implant retrievability after complete deployment and prior to its detachment from the TS Delivery System ✦ No active LV engagement minimizing LVOTO risk ✦ Suitable for the vast majority of MR patients	✦ **Early Feasibility Study** ✦ Ongoing patient screening for China case

*Note: * refers to TMV repair; ** refers to TMV replacement.*

Appendix 3: Product Features – TTV

Category	Product	Features	Progress
TTVr*	Edge to Edge (In-house development)	✦ Differentiated deployment for ease of use ✦ Unique lock mechanism for stable leaflet capture ✦ Low profile	✦ **Design stage**
TTVR*	TTVR product (In-house development)	✦ Catheter articulation for improved delivery and valve positioning ✦ Low profile ✦ Dry tissue	✦ **Design stage**
	TTVR product (Partnership with 4C)	✦ Supra-annular fit and atrial-only fixation	✦ **Design stage**

*Note: * refers to TTV repair; ** refers to TTV replacement.*

Appendix 4: Consolidated Income Statement

Unit: RMB'000	2023 1H	2022 1H
Revenue	176,442	124,782
Cost of sales	-59,819	-45,339
Gross profit	**116,623**	**79,443**
Other net income	43,698	11,089
Research and development costs	-109,494	-79,610
Distribution costs	-86,813	-61,048
Administrative expenses	-28,517	-33,940
Fair value changes in financial instruments	-32,999	981
Other operating costs	-37,918	-20,224
Loss from operations	**-135,420**	**-103,309**
Finance costs	-2,229	-2,915
Share of losses of associates	-23,504	-15,327
Share of losses of a joint venture	-14,476	-7
Loss before taxation	**-175,629**	**-121,558**
Income tax	-3,773	-822
Loss for the period and attributable to the equity shareholders of the Company	**-179,402**	**-122,380**

Appendix 4: Consolidated Balance Sheet

Unit: RMB'000	30-Jun-23	31-Dec-22
Non-current assets		
Property, plant and equipment	217,674	241,715
Intangible assets	153,702	163,119
Interest in a joint venture	-	14,520
Investment in associates	255,818	271,161
Other financial assets	-	12,490
Other non-current assets	27,121	26,488
Total Non-current assets	**654,315**	**729,493**
Current assets		
Inventories	111,877	114,115
Trade and other receivables	129,801	82,071
Pledged and time deposits	951,854	209,263
Cash and cash equivalents	1,052,658	1,866,319
Total current assets	**2,246,190**	**2,271,768**
Current liabilities		
Trade and other payables	101,393	115,609
Contract liabilities	4,855	6,087
Lease liabilities	28,557	31,041
Income tax payable	4,815	1,773
Derivative financial instruments	41,585	22719
Total current liabilities	**181,205**	**177,229**
Net current liabilities	**2,064,985**	**2,094,539**

Appendix 4: Consolidated Balance Sheet (Continued)

Unit: RMB'000	30-Jun-23	31-Dec-22
Non-current liabilities		
Lease liabilities	54,247	64,427
Deferred income	6,180	5,890
Derivative financial liabilities	-	-
Total non-current liabilities	**60,427**	**70,317**
CAPITAL AND RESERVES		
Share capital	83	83
Reserves	2,658,790	2,753,632
TOTAL EQUITY	**2,658,873**	**2,753,715**

Our Mission

To provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases



MicroPort™
心通医疗